Obstet Gynecol
Self-swabs and HPV-first: ACOG updates cervical cancer screening playbook
Clinical Takeaway: For average-risk patients ages 30 to 65, make primary high-risk HPV testing your default screening strategy—and offer patient-collected HPV testing every 3 years when preferred and supported by appropriate follow-up systems.
ACOG has released updated cervical cancer screening guidance in Obstetrics & Gynecology, marking the first time its recommendations formally include patient-collected high-risk human papillomavirus (hrHPV) testing as an option. The guidance endorses the 2026 Women’s Preventive Services Initiative recommendations and reflects a growing shift toward HPV-first screening strategies designed to improve access and equity.
For average-risk patients ages 30 to 65, primary hrHPV testing every 5 years is now the preferred screening approach. As a new option, patients in this age group may self-collect a vaginal sample for primary hrHPV testing every 3 years, but only if they prefer this method and the practice has systems in place for test processing, results notification, documentation, and timely follow-up of abnormal findings. Self-collection may be offered using FDA-approved assays and is intended to reduce barriers for patients who delay or avoid in-office pelvic exams.
Cytology-based screening remains unchanged for patients ages 21 to 29, who should continue Pap testing alone every 3 years. For patients older than 65, recommendations for discontinuing screening are unchanged, with continued screening advised for those without adequate prior negative results or with higher-risk histories.
While co-testing and cytology alone are still discussed in the full guidance, ACOG emphasizes hrHPV testing as the cornerstone of modern screening, reflecting its higher sensitivity for detecting cervical precancer.
“Too many people in the United States are needlessly suffering from cervical cancer,” said ACOG President Steven J. Fleischman, MD in a statement. “Underscreening—and lack of screening—is the most significant contributor to the development of this largely preventable illness.”
Overall, the guideline underscores a practical message for clinicians: prioritize HPV-based screening, tailor options to patient preferences, and ensure infrastructure is in place to support newer screening pathways that may help reach patients who have historically been left behind.
Source: (2026, April 24). Obstet Gynecol. Screening for Cervical Cancer